by
The global Drug Eluting Balloon Market is estimated to be valued at US$ 667.78 Mn in 2023 and is expected to exhibit a CAGR of 8.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Drug eluting balloons are medical angioplasty balloons coated with an antiproliferative drug. They help prevent re-narrowing or renarrowing of arteries after balloon angioplasty procedures. DEB treatment is needed to prevent restenosis or reblockage of arteries.
Market key trends:
One of the key trends in the drug eluting balloon market is the increasing adoption of combination therapy. Combination therapy involves the use of DEB along with drug-coated stents. Combination therapies help minimize edge effects and deliver optimal drug dose to blockages. Some studies have shown combination therapy to be more effective than using DEBs or drug-coated stents alone in treating complex arterial blockages. The growing popularity of combination therapies is expected to drive revenue growth in the drug eluting balloon market during the forecast period.
Segment Analysis
The global drug eluting balloon market is segmented based on type, disease indication, end user and geography. By type, the drug eluting balloon market is categorized into plain old balloon angioplasty (POBA), drug coated balloon (DCB) and cutting balloons. The drug coated balloon (DCB) segment is dominating as it offers advanced treatment option with lower restenosis rates compared to POBA balloons. By disease indication, the market is classified into coronary artery diseases and peripheral artery diseases. The coronary artery diseases segment accounts for the largest share owing to rising prevalence of CVDs globally. By end user, the market is divided into hospitals, cardiac centers and ambulatory surgical centers. Hospitals dominate the segment owing to availability of advanced healthcare facilities and medical reimbursement policies.
Key Takeaways
The Global Drug Eluting Balloon Market Size is expected to witness high growth, exhibiting CAGR of 8.3% over the forecast period, due to increasing prevalence of coronary and peripheral artery diseases.
Regional analysis – North America is expected to dominate the global drug eluting balloon market during the forecast period. This is attributed to growing geriatric population, rising obesity rates and increasing adoption of DES in the region. However, Asia Pacific region is anticipated to grow at the highest CAGR due to rising healthcare expenditure, availability of low-cost drugs and medical devices, and growing medical tourism in the region.
Key players – Key players operating in the drug eluting balloon market are Medtronic, Becton Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik. Medtronic dominates the market owing to its robust product portfolio and global brand presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
